West Pharmaceutical Services, Inc. (NYSE: WST) Stock Competitors & Peer Comparison
See WST's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for WST and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| WST | $356.46 | +2.85% | 24.8B | 44.29 | $7.97 | +0.25% |
| ISRG | $382.20 | -2.30% | 140.5B | 41.34 | $9.62 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.00% |
| BDX | $189.26 | +4.70% | 51.7B | 14.43 | $13.00 | +2.00% |
| MDLN | $32.94 | -3.47% | 28.7B | 24.85 | $1.36 | N/A |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $89.16 | +1.96% | 15.2B | 12.37 | $7.10 | N/A |
| COO | $76.71 | +1.25% | 15B | 16.83 | $4.56 | N/A |
| BAX | $26.32 | +1.45% | 13.8B | 12.82 | $2.08 | +0.75% |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.00% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
WST vs ISRG Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, ISRG has a market cap of 140.5B. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while ISRG trades at $382.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas ISRG's P/E ratio is 41.34. In terms of profitability, WST's ROE is +0.19%, compared to ISRG's ROE of +0.18%. Regarding short-term risk, WST is less volatile compared to ISRG. This indicates lower risk in terms of short-term price fluctuations for WST.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDXA)
WST vs BDXA Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas BDXA's P/E ratio is 45.70. In terms of profitability, WST's ROE is +0.19%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, WST is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for WST.Check BDXA's competition here
Becton, Dickinson and Company (NYSE: BDX)
WST vs BDX Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, BDX has a market cap of 51.7B. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while BDX trades at $189.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas BDX's P/E ratio is 14.43. In terms of profitability, WST's ROE is +0.19%, compared to BDX's ROE of +0.04%. Regarding short-term risk, WST is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for WST.Check BDX's competition here
Medline Inc. (NASDAQ: MDLN)
WST vs MDLN Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, MDLN has a market cap of 28.7B. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while MDLN trades at $32.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas MDLN's P/E ratio is 24.85. In terms of profitability, WST's ROE is +0.19%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, WST is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for WST.Check MDLN's competition here
Hologic, Inc. (NASDAQ: HOLX)
WST vs HOLX Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas HOLX's P/E ratio is 31.54. In terms of profitability, WST's ROE is +0.19%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, WST is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for WST.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
WST vs SOLV Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, SOLV has a market cap of 15.2B. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while SOLV trades at $89.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas SOLV's P/E ratio is 12.37. In terms of profitability, WST's ROE is +0.19%, compared to SOLV's ROE of +0.29%. Regarding short-term risk, WST is more volatile compared to SOLV. This indicates higher risk in terms of short-term price fluctuations for WST.Check SOLV's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
WST vs COO Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, COO has a market cap of 15B. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while COO trades at $76.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas COO's P/E ratio is 16.83. In terms of profitability, WST's ROE is +0.19%, compared to COO's ROE of +0.03%. Regarding short-term risk, WST is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for WST.Check COO's competition here
Baxter International Inc. (NYSE: BAX)
WST vs BAX Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, BAX has a market cap of 13.8B. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while BAX trades at $26.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas BAX's P/E ratio is 12.82. In terms of profitability, WST's ROE is +0.19%, compared to BAX's ROE of -0.17%. Regarding short-term risk, WST is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for WST.Check BAX's competition here
Becton, Dickinson and Company (NYSE: BDXB)
WST vs BDXB Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas BDXB's P/E ratio is 7.60. In terms of profitability, WST's ROE is +0.19%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, WST is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for WST.Check BDXB's competition here
Repligen Corporation (NASDAQ: RGEN)
WST vs RGEN Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, RGEN has a market cap of 10B. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while RGEN trades at $183.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas RGEN's P/E ratio is 97.98. In terms of profitability, WST's ROE is +0.19%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, WST is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for WST.Check RGEN's competition here
Avantor, Inc. (NYSE: AVTR)
WST vs AVTR Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, AVTR has a market cap of 9.5B. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while AVTR trades at $14.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas AVTR's P/E ratio is 16.44. In terms of profitability, WST's ROE is +0.19%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, WST is less volatile compared to AVTR. This indicates lower risk in terms of short-term price fluctuations for WST.Check AVTR's competition here
AptarGroup, Inc. (NYSE: ATR)
WST vs ATR Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, ATR has a market cap of 8.5B. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while ATR trades at $132.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas ATR's P/E ratio is 23.24. In terms of profitability, WST's ROE is +0.19%, compared to ATR's ROE of +0.14%. Regarding short-term risk, WST is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for WST.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
WST vs BLCO Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, BLCO has a market cap of 6.2B. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while BLCO trades at $17.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas BLCO's P/E ratio is 26.85. In terms of profitability, WST's ROE is +0.19%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, WST is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for WST.Check BLCO's competition here
Teleflex Incorporated (NYSE: TFX)
WST vs TFX Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, TFX has a market cap of 6B. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while TFX trades at $136.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas TFX's P/E ratio is 15.54. In terms of profitability, WST's ROE is +0.19%, compared to TFX's ROE of -0.32%. Regarding short-term risk, WST is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for WST.Check TFX's competition here
Stevanato Group S.p.A. (NYSE: STVN)
WST vs STVN Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, STVN has a market cap of 5.9B. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while STVN trades at $22.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas STVN's P/E ratio is 32.92. In terms of profitability, WST's ROE is +0.19%, compared to STVN's ROE of +0.09%. Regarding short-term risk, WST is less volatile compared to STVN. This indicates lower risk in terms of short-term price fluctuations for WST.Check STVN's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
WST vs MMSI Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, MMSI has a market cap of 5.5B. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while MMSI trades at $90.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas MMSI's P/E ratio is 23.52. In terms of profitability, WST's ROE is +0.19%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, WST is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for WST.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
WST vs ICUI Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, ICUI has a market cap of 4.7B. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while ICUI trades at $185.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas ICUI's P/E ratio is 23.38. In terms of profitability, WST's ROE is +0.19%, compared to ICUI's ROE of +0.01%. Regarding short-term risk, WST is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for WST.Check ICUI's competition here
Envista Holdings Corp (NYSE: NVST)
WST vs NVST Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, NVST has a market cap of 4.5B. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while NVST trades at $27.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas NVST's P/E ratio is 18.93. In terms of profitability, WST's ROE is +0.19%, compared to NVST's ROE of +0.04%. Regarding short-term risk, WST is more volatile compared to NVST. This indicates higher risk in terms of short-term price fluctuations for WST.Check NVST's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
WST vs PLSE Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, PLSE has a market cap of 3.3B. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while PLSE trades at $47.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas PLSE's P/E ratio is -39.85. In terms of profitability, WST's ROE is +0.19%, compared to PLSE's ROE of -0.94%. Regarding short-term risk, WST is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for WST.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
WST vs ATRC Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, ATRC has a market cap of 2.4B. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while ATRC trades at $47.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas ATRC's P/E ratio is 1478.57. In terms of profitability, WST's ROE is +0.19%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, WST is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for WST.Check ATRC's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
WST vs XRAY Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, XRAY has a market cap of 2.2B. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while XRAY trades at $10.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas XRAY's P/E ratio is 7.71. In terms of profitability, WST's ROE is +0.19%, compared to XRAY's ROE of -0.40%. Regarding short-term risk, WST is less volatile compared to XRAY. This indicates lower risk in terms of short-term price fluctuations for WST.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
WST vs LMAT Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, LMAT has a market cap of 1.9B. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while LMAT trades at $82.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas LMAT's P/E ratio is 30.83. In terms of profitability, WST's ROE is +0.19%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, WST is more volatile compared to LMAT. This indicates higher risk in terms of short-term price fluctuations for WST.Check LMAT's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
WST vs BLFS Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, BLFS has a market cap of 1.8B. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while BLFS trades at $37.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas BLFS's P/E ratio is -172.56. In terms of profitability, WST's ROE is +0.19%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, WST is less volatile compared to BLFS. This indicates lower risk in terms of short-term price fluctuations for WST.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
WST vs AZTA Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, AZTA has a market cap of 1.6B. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while AZTA trades at $36.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas AZTA's P/E ratio is 84.81. In terms of profitability, WST's ROE is +0.19%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, WST is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for WST.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
WST vs KMTS Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, KMTS has a market cap of 1.6B. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while KMTS trades at $27.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas KMTS's P/E ratio is -11.83. In terms of profitability, WST's ROE is +0.19%, compared to KMTS's ROE of -0.59%. Regarding short-term risk, WST is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for WST.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
WST vs STAA Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, STAA has a market cap of 1.2B. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while STAA trades at $23.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas STAA's P/E ratio is 43.26. In terms of profitability, WST's ROE is +0.19%, compared to STAA's ROE of +0.01%. Regarding short-term risk, WST is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for WST.Check STAA's competition here
QuidelOrtho Corporation (NASDAQ: QDEL)
WST vs QDEL Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, QDEL has a market cap of 941M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while QDEL trades at $14.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas QDEL's P/E ratio is 10.30. In terms of profitability, WST's ROE is +0.19%, compared to QDEL's ROE of -0.55%. Regarding short-term risk, WST is less volatile compared to QDEL. This indicates lower risk in terms of short-term price fluctuations for WST.Check QDEL's competition here
Atrion Corporation (NASDAQ: ATRI)
WST vs ATRI Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas ATRI's P/E ratio is 64.50. In terms of profitability, WST's ROE is +0.19%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, WST is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for WST.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
WST vs ANGO Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, ANGO has a market cap of 664.2M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while ANGO trades at $15.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas ANGO's P/E ratio is -41.21. In terms of profitability, WST's ROE is +0.19%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, WST is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for WST.Check ANGO's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
WST vs NNNN Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, NNNN has a market cap of 366.5M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while NNNN trades at $7.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas NNNN's P/E ratio is 120.66. In terms of profitability, WST's ROE is +0.19%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, WST is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for WST.Check NNNN's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
WST vs SMTI Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, SMTI has a market cap of 315.1M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while SMTI trades at $34.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas SMTI's P/E ratio is -571.33. In terms of profitability, WST's ROE is +0.19%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, WST is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for WST.Check SMTI's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
WST vs OSUR Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, OSUR has a market cap of 258.2M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while OSUR trades at $3.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas OSUR's P/E ratio is -6.82. In terms of profitability, WST's ROE is +0.19%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, WST is more volatile compared to OSUR. This indicates higher risk in terms of short-term price fluctuations for WST.Check OSUR's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
WST vs INFU Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, INFU has a market cap of 245.8M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while INFU trades at $12.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas INFU's P/E ratio is 29.71. In terms of profitability, WST's ROE is +0.19%, compared to INFU's ROE of +0.15%. Regarding short-term risk, WST is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for WST.Check INFU's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
WST vs UTMD Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, UTMD has a market cap of 229.6M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while UTMD trades at $73.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas UTMD's P/E ratio is 21.34. In terms of profitability, WST's ROE is +0.19%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, WST is more volatile compared to UTMD. This indicates higher risk in terms of short-term price fluctuations for WST.Check UTMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
WST vs PDEX Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, PDEX has a market cap of 213.7M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while PDEX trades at $66.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas PDEX's P/E ratio is 23.57. In terms of profitability, WST's ROE is +0.19%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, WST is more volatile compared to PDEX. This indicates higher risk in terms of short-term price fluctuations for WST.Check PDEX's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
WST vs KRMD Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, KRMD has a market cap of 152.5M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while KRMD trades at $3.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas KRMD's P/E ratio is -83.00. In terms of profitability, WST's ROE is +0.19%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, WST is more volatile compared to KRMD. This indicates higher risk in terms of short-term price fluctuations for WST.Check KRMD's competition here
Microbot Medical Inc. (NASDAQ: MBOT)
WST vs MBOT Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, MBOT has a market cap of 70.6M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while MBOT trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas MBOT's P/E ratio is -5.96. In terms of profitability, WST's ROE is +0.19%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, WST is less volatile compared to MBOT. This indicates lower risk in terms of short-term price fluctuations for WST.Check MBOT's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
WST vs AKYA Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas AKYA's P/E ratio is -1.34. In terms of profitability, WST's ROE is +0.19%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, WST is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for WST.Check AKYA's competition here
Daxor Corporation (NASDAQ: DXR)
WST vs DXR Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, DXR has a market cap of 60.1M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while DXR trades at $10.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas DXR's P/E ratio is 5.67. In terms of profitability, WST's ROE is +0.19%, compared to DXR's ROE of +0.22%. Regarding short-term risk, WST is less volatile compared to DXR. This indicates lower risk in terms of short-term price fluctuations for WST.Check DXR's competition here
SkyAI, Inc. (NASDAQ: STSS)
WST vs STSS Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas STSS's P/E ratio is -0.02. In terms of profitability, WST's ROE is +0.19%, compared to STSS's ROE of -1.54%. Regarding short-term risk, WST is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for WST.Check STSS's competition here
Nephros, Inc. (NASDAQ: NEPH)
WST vs NEPH Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, NEPH has a market cap of 51.7M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while NEPH trades at $4.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas NEPH's P/E ratio is 79.33. In terms of profitability, WST's ROE is +0.19%, compared to NEPH's ROE of +0.16%. Regarding short-term risk, WST is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for WST.Check NEPH's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
WST vs OMIC Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas OMIC's P/E ratio is -0.58. In terms of profitability, WST's ROE is +0.19%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, WST is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for WST.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
WST vs IGAP Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas IGAP's P/E ratio is -10.52. In terms of profitability, WST's ROE is +0.19%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, WST is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for WST.Check IGAP's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
WST vs POCI Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, POCI has a market cap of 48.6M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while POCI trades at $4.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas POCI's P/E ratio is -6.17. In terms of profitability, WST's ROE is +0.19%, compared to POCI's ROE of -0.37%. Regarding short-term risk, WST is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for WST.Check POCI's competition here
Milestone Scientific Inc. (AMEX: MLSS)
WST vs MLSS Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, MLSS has a market cap of 42.4M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while MLSS trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas MLSS's P/E ratio is -7.99. In terms of profitability, WST's ROE is +0.19%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, WST is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for WST.Check MLSS's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
WST vs HBIO Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, HBIO has a market cap of 31.9M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while HBIO trades at $7.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas HBIO's P/E ratio is -19.67. In terms of profitability, WST's ROE is +0.19%, compared to HBIO's ROE of -0.92%. Regarding short-term risk, WST is less volatile compared to HBIO. This indicates lower risk in terms of short-term price fluctuations for WST.Check HBIO's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
WST vs SDC Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas SDC's P/E ratio is -0.03. In terms of profitability, WST's ROE is +0.19%, compared to SDC's ROE of -1.96%. Regarding short-term risk, WST is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for WST.Check SDC's competition here
Invacare Corporation (NYSE: IVC)
WST vs IVC Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas IVC's P/E ratio is -0.79. In terms of profitability, WST's ROE is +0.19%, compared to IVC's ROE of -0.46%. Regarding short-term risk, WST is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for WST.Check IVC's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
WST vs ZJYL Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, ZJYL has a market cap of 24.1M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while ZJYL trades at $3.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas ZJYL's P/E ratio is 19.25. In terms of profitability, WST's ROE is +0.19%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, WST is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for WST.Check ZJYL's competition here
Retractable Technologies, Inc. (AMEX: RVP)
WST vs RVP Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, RVP has a market cap of 21.7M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while RVP trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas RVP's P/E ratio is -2.20. In terms of profitability, WST's ROE is +0.19%, compared to RVP's ROE of -0.05%. Regarding short-term risk, WST is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for WST.Check RVP's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
WST vs RGNT Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, RGNT has a market cap of 15.6M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while RGNT trades at $2.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas RGNT's P/E ratio is -0.09. In terms of profitability, WST's ROE is +0.19%, compared to RGNT's ROE of N/A. Regarding short-term risk, WST is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for WST.Check RGNT's competition here
Femasys Inc. (NASDAQ: FEMY)
WST vs FEMY Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, FEMY has a market cap of 7.9M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while FEMY trades at $2.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas FEMY's P/E ratio is -7.21. In terms of profitability, WST's ROE is +0.19%, compared to FEMY's ROE of -2.26%. Regarding short-term risk, WST is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for WST.Check FEMY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
WST vs NSTG Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas NSTG's P/E ratio is -0.03. In terms of profitability, WST's ROE is +0.19%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, WST is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for WST.Check NSTG's competition here
Lucyd, Inc (NASDAQ: LUCY)
WST vs LUCY Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, LUCY has a market cap of 4.4M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while LUCY trades at $0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas LUCY's P/E ratio is -0.41. In terms of profitability, WST's ROE is +0.19%, compared to LUCY's ROE of -0.89%. Regarding short-term risk, WST is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for WST.Check LUCY's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
WST vs POAI Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas POAI's P/E ratio is -0.03. In terms of profitability, WST's ROE is +0.19%, compared to POAI's ROE of -21.19%. Regarding short-term risk, WST is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for WST.Check POAI's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
WST vs NXGL Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, NXGL has a market cap of 3.3M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while NXGL trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas NXGL's P/E ratio is -0.55. In terms of profitability, WST's ROE is +0.19%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, WST is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for WST.Check NXGL's competition here
GlucoTrack, Inc. (NASDAQ: GCTK)
WST vs GCTK Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, GCTK has a market cap of 2.7M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while GCTK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas GCTK's P/E ratio is -0.02. In terms of profitability, WST's ROE is +0.19%, compared to GCTK's ROE of -21.36%. Regarding short-term risk, WST is less volatile compared to GCTK. This indicates lower risk in terms of short-term price fluctuations for WST.Check GCTK's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
WST vs MHUA Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas MHUA's P/E ratio is 0.25. In terms of profitability, WST's ROE is +0.19%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, WST is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for WST.Check MHUA's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
WST vs GMVD Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas GMVD's P/E ratio is -0.01. In terms of profitability, WST's ROE is +0.19%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, WST is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for WST.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
WST vs GMVDW Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas GMVDW's P/E ratio is N/A. In terms of profitability, WST's ROE is +0.19%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, WST is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for WST.Check GMVDW's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
WST vs NXGLW Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, NXGLW has a market cap of 1.5M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while NXGLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas NXGLW's P/E ratio is -0.05. In terms of profitability, WST's ROE is +0.19%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, WST is more volatile compared to NXGLW. This indicates higher risk in terms of short-term price fluctuations for WST.Check NXGLW's competition here
Avinger, Inc. (NASDAQ: AVGR)
WST vs AVGR Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas AVGR's P/E ratio is -0.05. In terms of profitability, WST's ROE is +0.19%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, WST is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for WST.Check AVGR's competition here
Lucyd, Inc (NASDAQ: LUCYW)
WST vs LUCYW Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas LUCYW's P/E ratio is N/A. In terms of profitability, WST's ROE is +0.19%, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, WST is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for WST.Check LUCYW's competition here
Apria, Inc. (NASDAQ: APR)
WST vs APR Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, APR has a market cap of 0. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas APR's P/E ratio is 22.59. In terms of profitability, WST's ROE is +0.19%, compared to APR's ROE of +9.81%. Regarding short-term risk, WST is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for WST.Check APR's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
WST vs HRC Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, HRC has a market cap of 0. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas HRC's P/E ratio is 41.92. In terms of profitability, WST's ROE is +0.19%, compared to HRC's ROE of +0.14%. Regarding short-term risk, WST is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for WST.Check HRC's competition here
IntriCon Corporation (NASDAQ: IIN)
WST vs IIN Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, IIN has a market cap of 0. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas IIN's P/E ratio is 226.45. In terms of profitability, WST's ROE is +0.19%, compared to IIN's ROE of -0.00%. Regarding short-term risk, WST is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for WST.Check IIN's competition here
Analogic Corporation (NASDAQ: ALOG)
WST vs ALOG Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, ALOG has a market cap of 0. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas ALOG's P/E ratio is 40.93. In terms of profitability, WST's ROE is +0.19%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, WST is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for WST.Check ALOG's competition here
Invuity, Inc. (NASDAQ: IVTY)
WST vs IVTY Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, IVTY has a market cap of 0. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas IVTY's P/E ratio is -3.80. In terms of profitability, WST's ROE is +0.19%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, WST is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for WST.Check IVTY's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
WST vs ATRS Comparison August 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 24.8B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, WST is priced at $356.46 on the NYSE, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 44.29, whereas ATRS's P/E ratio is 14.95. In terms of profitability, WST's ROE is +0.19%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, WST is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for WST.Check ATRS's competition here